Search
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. … [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic IndexHydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigationalHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. … [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.
Synonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineProducts: Hydroxycarbamid 1A Pharma 100 mg - Filmtabletten, Hydroxycarbamid 1A Pharma 1000 mg - FilmtablettenTranylcypromine
go.drugbank.com/drugs/DB00752ApprovedInvestigationalTranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. … A propylamine formed from the cyclization of the side chain of amphetamine.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesOlaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell … [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexRivastigmine
go.drugbank.com/drugs/DB00989ApprovedInvestigationalRivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. … Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type.
Categories: Compounds used in a research, industrial, or household settingProducts: RIVASTIGMIN ZEN 13.3MG/24H, RIVASTIGMIN AL 3MG HARTClobazam
go.drugbank.com/drugs/DB00349ApprovedIllicitInvestigational[A256868] Additionally, clobazam is believed to be a partial agonist to the GABA<sub>A</sub> receptor rather than non-selective full receptor agonists like 1,4-benzodiazepines, thus potentially explaining … [A256913] Unlike older 1,4-benzodiazepines, clobazam has a better side-effects profile, particularly less sedative and amnesic effects.
Categories: GABA-A Receptor AgonistsStannous chloride
go.drugbank.com/drugs/DB11056ApprovedStannous chloride is used as a source of tin in radiopharmaceutical kits. … Tin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700].
Secukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque
Products: Fraizeron 150mg/ml solution for injection in pre-filled pen, Fraizeron 300mg/2ml solution for injection in pre-filled penPholcodine
go.drugbank.com/drugs/DB09209ApprovedIllicit[A31742] Pholcodine is not prescribed in the United States where it is classed as a Schedule I drug. It is categorized as Class B drug in the UK and officially taken out of the shelves in 2008. … [A31738] Pholcodine activity is the suppression of unproductive cough and it also has a mild sedative effect with little or no analgesic effects.
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigationalbevacizumab a therapeutic role in both oncology and ophthalmology. … [A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target.
Categories: Complex MixturesSynonyms: Bei Fa Zhu Dankang